Scarica l'app Stockscreener
15.06
0.40%
-0.06
Dopo l'orario di chiusura:
15.06
Precedente Chiudi:
$15.12
Aprire:
$14.69
Volume 24 ore:
904.32K
Relative Volume:
0.56
Capitalizzazione di mercato:
$1.31B
Reddito:
-
Utile/perdita netta:
$-162.45M
Rapporto P/E:
-8.0768
EPS:
-1.8646
Flusso di cassa netto:
$-146.72M
1 W Prestazione:
+6.66%
1M Prestazione:
-37.30%
6M Prestazione:
+35.19%
1 anno Prestazione:
+352.25%
Intervallo 1D:
$14.62
$15.12
Intervallo di 1 settimana:
$13.21
$15.99
Portata 52W:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Nome
Olema Pharmaceuticals Inc
Settore
Industria
Telefono
(415) 651-3316
Indirizzo
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
15.06 | 1.31B | 0 | -162.45M | -146.72M | -1.8646 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Peer Perform |
| 2026-03-19 | Ripresa | Jefferies | Buy |
| 2026-02-11 | Iniziato | Stifel | Buy |
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-10-08 | Iniziato | Guggenheim | Buy |
| 2025-08-12 | Reiterato | Citigroup | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2024-01-30 | Iniziato | Citigroup | Buy |
| 2023-07-21 | Iniziato | Oppenheimer | Outperform |
| 2023-05-05 | Iniziato | CapitalOne | Overweight |
| 2023-02-22 | Iniziato | Credit Suisse | Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Iniziato | H.C. Wainwright | Neutral |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2020-12-14 | Iniziato | Canaccord Genuity | Buy |
| 2020-12-14 | Iniziato | Cowen | Outperform |
| 2020-12-14 | Iniziato | JP Morgan | Overweight |
| 2020-12-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Olema Pharmaceuticals Inc Borsa (OLMA) Ultime notizie
Olema oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
OLMA SEC FilingsOlema Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
OLMA Forecast, Price Target & Analyst Ratings | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
OLMA Technical Analysis & Stock Price Forecast - Intellectia AI
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 8.4%Still a Buy? - MarketBeat
Targets Report: How does Olema Pharmaceuticals Inc perform in inflationary periodsMarket Sentiment Review & Technical Buy Zone Confirmation - baoquankhu1.vn
A Look At Olema Pharmaceuticals (OLMA) Valuation After Earnings And New Shelf Registration Filing - Sahm
Hennion & Walsh Asset Management Inc. Increases Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals Inc at Citi Oncology Leadership Summit (Virtual) Transcript - GuruFocus
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Wolfe Research initiates coverage of Olema Pharmaceuticals (OLMA) with peer perform recommendation - MSN
Wolfe Research Initiates Coverage on Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals seeks senior director to lead accounting operations and financial reporting - Traders Union
Buybacks Report: Will Olema Pharmaceuticals Inc outperform its industry peers2026 Key Highlights & Expert Approved Trade Ideas - baoquankhu1.vn
Aug PostEarnings: What are analysts price targets for Olema Pharmaceuticals IncWeekly Stock Report & Reliable Intraday Trade Alerts - baoquankhu1.vn
Oppenheimer maintains Olema Pharmaceuticals (OLMA) outperform recommendation - MSN
Jim Cramer on Olema Pharmaceuticals: "Too risky for me" - msn.com
Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me” - Insider Monkey
Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility - Yahoo Finance
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? - AOL.com
Invus entities disclose 4.5% stake in Olema (OLMA) on Schedule 13G - Stock Titan
Jefferies Adjusts Price Target for Olema Pharmaceuticals (OLMA) - GuruFocus
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Jefferies Adjusts Price Target for Olema Pharmaceuticals (OLMA) | OLMA Stock News - GuruFocus
Olema Pharmaceuticals (OLMA) Is Down 6.7% After Posting Wider Losses And Filing New Stock Shelf - simplywall.st
Jefferies Financial Group Begins Coverage on Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Jefferies initiates Olema Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
LifeSci Capital reiterates a buy on Olema Pharmaceuticals (OLMA) - MSN
JP Morgan Raises Price Target for Olema Pharmaceuticals (OLMA) | - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Olema Pharmaceuticals (OLMA) Drops 33.4% Over Past Month, Reasons Suggest a Potential Turnaround Ahead - Bitget
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Olema Pharmaceuticals (OLMA) Receives Updated Price Target by Go - GuruFocus
The Goldman Sachs Group Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
HC Wainwright Issues Optimistic Outlook for OLMA Earnings - MarketBeat
OLMA: Guggenheim Lowers Price Target While Maintaining Buy Ratin - GuruFocus
Olema Pharmaceuticals (OLMA) Receives Increased Price Target fro - GuruFocus
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting - Bitget
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Citigroup Forecasts Strong Price Appreciation for Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 5.2% Following Analyst Downgrade - MarketBeat
OLMA: Guggenheim Lowers Price Target While Maintaining Buy Rating | OLMA Stock News - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Cut to $38.00 by Analysts at Guggenheim - MarketBeat
Guggenheim lowers Olema Pharmaceuticals price target on trial timing By Investing.com - Investing.com Canada
Breakout Zone: Should I invest in Olema Pharmaceuticals Inc before earningsWeekly Stock Recap & AI Powered Market Trend Analysis - baoquankhu1.vn
Decoding Olema Pharmaceuticals inc (OLMA): A Strategic SWOT Insi - GuruFocus
Olema Pharmaceuticals (OLMA) Stock Rises 9% After Q4 Earnings Beat - MEXC
Short Covering: Does Olema Pharmaceuticals Inc have pricing powerVolume Spike & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch - The Motley Fool
Biotech shares surge almost 300% as $68.7 million investment backs breast cancer treatment aiming for 2027 debut - Bitget
Olema Pharmaceuticals Inc Azioni (OLMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):